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Genetic association study of the P-type ATPase ATP13A2 in
late-onset Parkinson's disease
Abstract
A role of ATP13A2 in early-onset Parkinsonism (EOP) has been proposed. Conversely, the contribution
of this ATPase to late-onset Parkinson's disease (PD) remains unexplored. We therefore conducted a
case-control association study in this age-of-onset group with PD. The initial sample was of German
origin and consisted of 220 patients with late-onset PD (mean age of onset 60.1 years) and 232
age-matched unrelated controls. Five single nucleotide polymorphisms (SNPs) covering ATP13A2 and
its common haplotypes were genotyped. The overall association results in this sample were negative.
Interestingly, gender stratification gave a positive result for SNP rs11203280 (P(UNC) = 0.016) in men.
This result could not be reproduced in a replication sample of German and Serbian origin composed of
161 patients with late-onset PD (mean age of onset 51.7 years) and 150 age- and ethnic-matched
controls. In conclusion, we found no consistent evidence for an association between ATP13A2 and
late-onset PD.
For Peer Review
                                                                                                                     Rakovic et al        1 
Genetic association study of the P-type ATPase  
ATP13A2 in late onset Parkinson disease 
 
Aleksandar Rakovic, MSc1,2,*, Barbara Stiller, MSc3,4,5,*, Ana Djarmati, PhD1,2, Antonia 
Flaquer, MSc7, Jan Freudenberg, MD8, Mohammad-Reza Toliat, PhD4,6, Michael Linnebank, 
MD9, ,Vladimir Kostic, MD10, Katja Lohmann, PhD1,2, Sebastian Paus MD9, Peter Nürnberg, 
PhD4,6,11, Christian Kubisch, MD3,4,5,6,11, Christine Klein, MD1,2, Ullrich Wüllner, MD9 and 
Alfredo Ramirez, MD3,4,5 
 
1Department of Neurology and 2Department of Human Genetics, University of Lübeck, 
Lübeck, Germany 
3Institute of Human Genetics, 4Institute for Genetics, 5Center for Molecular Medicine 
Cologne, 6Cologne Center for Genomics, and 11Cologne Excellence Cluster on Cellular Stress 
Responses in Aging-Associated Diseases (CECEAD), University of Cologne, Cologne, 
Germany  
7Institute for Medical Biometry, Informatics and Epidemiology, University of Bonn, Bonn, 
Germany 
8Laboratories of Neurogenetics, Department of Neurology, University of California at San 
Franscisco, San Francisco, CA 94143, USA 
9Department of Neurology, University of Bonn, Bonn, Germany 
10Department of Neurology, University of Belgrade, Belgrade, Serbia 
*These authors contributed equally 
 
Running title: Role of ATP13A2 in Parkinson disease 
 
Corresponding author: Alfredo Ramirez, MD 
    Institute of Human Genetics 
    University of Cologne 
    Kerpener Strasse 34 
50931 Cologne, Germany 
    phone: +49-221-478 86828 
    fax: +49-221-478 86435 
    email: alfredo.ramirez@uk-koeln.de 
 
Disclosure: The authors report no conflicts of interest. 
___________________________________________________________________ 
Date of submission:        14/02/08 
Number of words (main text):      1530 
Number of words (abstract):       150 
Number of figures/tables:       2 
Number of supplementary files:      0 
Title length (characters):       86 
Page 1 of 24
John Wiley & Sons
Movement Disorders
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Peer Review
                                                                                                                     Rakovic et al        2 
Abstract 
A role of ATP13A2 in early onset parkinsonism (EOP) has been proposed. Conversely, the 
contribution of this ATPase to late onset Parkinson disease (PD) remains unexplored. We 
therefore conducted a case-control association study in this age-of-onset group with PD. The 
initial sample was of German origin and consisted of 220 late onset PD patients (mean age of 
onset 60.1 years) and 232 age-matched unrelated controls. Five single nucleotide 
polymorphisms (SNPs) covering ATP13A2 and its common haplotypes were genotyped. The 
overall association results in this sample were negative. Interestingly, gender stratification 
gave a positive result for SNP rs11203280 (PUNC=0.016) in men. This result could not be 
reproduced in a replication sample of German and Serbian origin composed of 161 late onset 
PD patients (mean age of onset 51.7 years) and 150 age- and ethnic-matched controls. In 
conclusion, we found no consistent evidence for an association between ATP13A2 and late 
onset PD. 
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Introduction 
Parkinson disease (PD) and parkinsonism are a heterogeneous group of common 
neurodegenerative disorders with a prevalence of approximately 3% in people over the age of 
65 years. Both diseases show several common clinical and pathological features, such as 
hypokinetic-rigid syndrome, tremor at rest, and nigral degeneration.1-3 Regarding the age of 
disease onset, the term early onset parkinsonism (EOP) describes a group of patients with 
onset of symptoms before the age of 40 years.4 
Several common key factors have been involved in the molecular etiology of PD and 
parkinsonism, including enhanced oxidative stress, mitochondrial dysfunction, accumulation 
of aberrant or misfolded proteins, and dysfunction of the ubiquitin-proteasome system (UPS) 
and the lysosome.5-7 In this regard, we have identified loss-of-function mutations in ATP13A2, 
a mainly neuronal P-type ATPase gene, the gene product of which is localized in the 
lysosome. Initially, mutations were found in two families affected by a rare form of EOP with 
dementia called Kufor-Rakeb disease (KRD).8 However, the clinical characterization of the 
KRD phenotype showed additional features beyond the spectrum of “pure” PD. Nevertheless, 
the presence of levodopa-responsive parkinsonism and the increased expression of ATP13A2 
in the brain of idiopathic PD patients raised the question whether variants in this gene could 
also be associated with idiopathic PD.8-10 This issue has attracted further attention by the 
identification of a homozygous missense mutation and two heterozygous mutations in EOP 
patients.11 However, whether ATP13A2 also contributes to the pathogenesis of late onset PD 
is currently unknown. Therefore, we investigated this question in two independent case-
control samples of late onset PD by a systematic single nucleotide polymorphism (SNP)-
based association study. Here we present the results of 5 SNPs which capture the predicted 
common haplotype variations of ATP13A2 locus. 
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Material and Methods 
Patients: After obtaining informed consent, all patients underwent a standardized 
neurological examination by a movement disorder specialist. The study was approved by the 
local university ethics committees. The diagnosis of PD was based on the UK Brain Bank 
diagnostic criteria (with the exception that positive family history was not regarded an 
exclusion criterion).12 Patients were collected at movement disorders centres in Bonn, 
Cologne, Luebeck, and Belgrade and represent consecutive series, not originating in a 
geographic isolate. The initial case- control sample was collected in Bonn and Cologne. 
Patients were included in this study only if the onset of symptoms was over the age of 40 
years and they had German background (i.e., both parents were born in Germany). Controls of 
this sample were included if their age was over 40 years and they had a German background. 
A replication sample of German and Serbian origin was collected in Luebeck and Belgrade. 
Family history was regarded positive if parkinsonism was reported for one first- or second-
degree relative. PD was rated using the Unified Parkinson Disease Rating Scale (UPDRS) III. 
A more detailed description of both patient and control samples including their ethnic 
background is found in table 1. 
 
SNP selection: Haplotype-tagging (ht-)SNPs were selected from the HapMap database 
(http://www.hapmap.org; version July 2006) to discriminate between all predicted common 
haplotypes (with an estimated frequency >5%) within haplotype blocks in the Central 
European sample. Haplotype blocks were defined as regions in which >85% of total 
haplotype diversity is covered by common haplotypes, using the program hapblock.13  
 
Genetic analysis: Initial SNP-genotyping on genomic DNA was performed on a TaqManTM 
platform with assays designed by Applied Biosystems. The SNP rs3754511 was genotyped 
using pyrosequencing. The genotyping of the replication sample was performed by RFLP for 
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SNPs rs2871775 and rs3754511, using HpaI and MspI restriction enzymes, respectively. 
Genotyping of rs3738815 and rs11203280 was carried out on a LightCycler (Roche 
Diagnostics). All primer sequences and experimental conditions are available from the 
authors.  
 
Statistics: First, quality control was applied to the dataset. Thus, individuals displaying a low 
call rate (one missing SNP) were removed from the analysis. SNPs passed the quality control 
when showing a call rate higher than 95%. The exact test described and implemented by 
Wigginton and colleagues was used to check for Hardy-Weinberg equilibrium (HWE).14 
Distribution of genotypes was consistent with HWE in both groups of cases and controls. 
Genotypes and allele distributions were compared between cases and controls for all SNPs 
using the global genotype test and Armitage trend test, genotypic test, dominant test, recessive 
test. To perform case-control tests on the distribution of a probabilistically inferred set, the 
haplotypes standard EM algorithm was used. All analyses were performed using the free open 
source PLINK v0.99r developed by Shaun Purcell et al.15 
 
Power calculation: A power analysis was performed with the Genetic Power calculator.16 
We estimate that, under the assumption of complete LD between the marker tested and the 
disease-causing variant, we had 77% power to detect a true difference in allele frequency 
between the 220 PD patients and 232 controls (i.e., in the first sample) with a single-marker 
association analysis (α=0.05), further assuming a frequency of the disease-associated allele A 
of 0.25, a relative risk of 1.5 for genotype Aa and of 2.25 for genotype AA, and a prevalence 
of PD in the general population over the age of 50 years of 1.5%. Using these parameters with 
both samples together the estimated power increases to 95%. 
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Results 
The initial genotyping involved 7 SNPs covering the entire ATP13A2 locus. The sample used 
for the first stage of our association analysis included a total of 452 unrelated individuals from 
Germany (Table 1). Although two SNPs failed the quality control and were omitted from the 
analysis, the remaining 5 SNPs described >90% of the most common haplotypes. Therefore, 
genotypic distributions between cases and control subjects were compared for these 5 SNPs. 
These comparisons were performed using different test models including a recessive model 
assuming homozygocity, dominant model, genotypic model, and additive model. Regardless 
which test was performed, the results for the first sample did not support a significant allelic 
or genotypic association with PD with a minimal p-value for rs11203280 of PUNC=0.134 
(Table 2). Interestingly, the same SNP showed a significant association in the men subgroup 
with an uncorrected p-value of PUNC =0.016. However, this result was not significant after 
permutation-based correction for the number of test performed (p>0.05). 
This finding prompted us to analyse a second independent sample of cases and controls. 
Especially since the initial sample had a reduced power to detect a true allelic difference. 
Thus, we genotyped the same 5 SNPs in a cohort containing 311 individuals of German and 
Serbian background (Table 1). The analysis revealed no association between this second 
sample and PD and no gender effect was observed in this second cohort (rs11203280 of 
PUNC=0.389 overall and PUNC =0.570 in men; Table 2). As expected, the analysis of both 
samples combined showed no association with PD (data not shown). To avoid any bias in the 
analysis due to population stratification in the second sample, we merged the German 
individuals from both samples to determine whether these initially observed differences were 
specific to German PD patients (Table 2). However, no positive association emerged from 
this analysis in either the complete sample and in the German men subgroup, best p-value at 
rs11203280 of PUNC =0.514 and PUNC =0.084, respectively. 
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Discussion 
We present here the data of a systematic case-control association study in two independent 
late onset PD samples. The overall results of our analysis did not support an association 
between ATP13A2 and PD. Interestingly, gender stratification of the initial sample showed a 
significant association for men with PD in the single marker analysis. Unfortunately, this 
finding did not withstand a correction for multiple testing. Nevertheless, we decided to test 
the veracity of this finding by increasing the power of detection of our study. Therefore, we 
analyzed a second independent sample of individuals with German and Serbian background. 
However, the gender effect could neither be replicated in the second sample nor in both 
samples combined. Furthermore, no gender effect was observed in the analysis of all German 
individuals from both samples. To confirm our findings, we analyzed the raw data for the 
ATP13A2 locus contained in two different genome wide association studies (GWA) 17, 18. This 
analysis revealed that all SNPs from our study were contained in one of the GWA 17 and that 
they showed no association between this ATPase gene and PD, either (data not shown). 
Interestingly, the cohort analyzed in this GWA was composed of white individuals from USA 
with an age of onset of PD ranging from 55 years to 84 years. Thus, our data combined with 
the results from Fung and colleagues strongly argue for a lack of association between 
ATP13A2 and late onset PD, at least in European and US populations. 
This negative association between SNPs within the ATP13A2 gene and PD is not a unique 
finding. Likewise, negative association were also reported for idiopathic PD and several 
common polymorphisms at gene loci involved in other monogenic forms of parkinsonism19, 
20
, with rare exceptions, such as common variants in α-synuclein.21  
In conclusion, we currently cannot conclude that common variants in the ATP13A2 locus play 
a major role in the molecular etiology of late onset PD. Yet, the question whether private 
mutations could be responsible for the PD in this age group remains open and further studies 
are warranted. 
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Legend to tables 
Table 1: General characteristics of the case control dataset. 
 
Table 2: Statistical analysis of SNPs with differential allele distribution between men and 
women 
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Abstract 
A role of ATP13A2 in early onset parkinsonism (EOP) has been proposed. Conversely, the 
contribution of this ATPase to late onset Parkinson disease (PD) remains unexplored. We 
therefore conducted a case-control association study in this age-of-onset group with PD. The 
initial sample was of German origin and consisted of 220 late onset PD patients (mean age of 
onset 60.1 years) and 232 age-matched unrelated controls. Five single nucleotide 
polymorphisms (SNPs) covering ATP13A2 and its common haplotypes were genotyped. The 
overall association results in this sample were negative. Interestingly, gender stratification 
gave a positive result for SNP rs11203280 (PUNC=0.016) in men. This result could not be 
reproduced in a replication sample of German and Serbian origin composed of 161 late onset 
PD patients (mean age of onset 51.7 years) and 150 age- and ethnic-matched controls. In 
conclusion, we found no consistent evidence for an association between ATP13A2 and late 
onset PD. 
 
Keywords: ATP13A2, Parkinson disease, association study, parkinsonism 
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Introduction 
Parkinson disease (PD) and parkinsonism are a heterogeneous group of common 
neurodegenerative disorders with a prevalence of approximately 3% in people over the age of 
65 years. Both diseases show several common clinical and pathological features, such as 
hypokinetic-rigid syndrome, tremor at rest, and nigral degeneration.1-3 Regarding the age of 
disease onset, the term early onset parkinsonism (EOP) describes a group of patients with 
onset of symptoms before the age of 40 years.4 
Several common key factors have been involved in the molecular etiology of PD and 
parkinsonism, including enhanced oxidative stress, mitochondrial dysfunction, accumulation 
of aberrant or misfolded proteins, and dysfunction of the ubiquitin-proteasome system (UPS) 
and the lysosome.5-7 In this regard, we have identified loss-of-function mutations in ATP13A2, 
a mainly neuronal P-type ATPase gene, the gene product of which is localized in the 
lysosome. Initially, mutations were found in two families affected by a rare form of EOP with 
dementia called Kufor-Rakeb disease (KRD).8 However, the clinical characterization of the 
KRD phenotype showed additional features beyond the spectrum of “pure” PD. Nevertheless, 
the presence of levodopa-responsive parkinsonism and the increased expression of ATP13A2 
in the brain of idiopathic PD patients raised the question wh ther variants in this gene could 
also be associated with idiopathic PD.8-10 This issue has attracted further attention by the 
identification of a homozygous missense mutation and two heterozygous mutations in EOP 
patients.11 However, whether ATP13A2 also contributes to the pathogenesis of late onset PD 
is currently unknown. Therefore, we investigated this question in two independent case-
control samples of late onset PD by a systematic single nucleotide polymorphism (SNP)-
based association study. Here we present the results of 5 SNPs which capture the predicted 
common haplotype variations of ATP13A2 locus. 
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Material and Methods 
Patients: After obtaining informed consent, all patients underwent a standardized 
neurological examination by a movement disorder specialist. The study was approved by the 
local university ethics committees. The diagnosis of PD was based on the UK Brain Bank 
diagnostic criteria (with the exception that positive family history was not regarded an 
exclusion criterion).12 Patients were collected at movement disorders centres in Bonn, 
Cologne, Luebeck, and Belgrade and represent consecutive series, not originating in a 
geographic isolate. The initial case- control sample was collected in Bonn and Cologne. 
Patients were included in this study only if the onset of symptoms was over the age of 40 
years and they had German background (i.e., both parents were born in Germany). Controls of 
this sample were included if their age was over 40 years and they had a German background. 
A replication sample of German and Serbian origin was collected in Luebeck and Belgrade. 
Family history was regarded positive if parkinsonism was reported for one first- or second-
degree relative. PD was rated using the Unified Parkinson Disease Rating Scale (UPDRS) III. 
A more detailed description of both patient and control samples including their ethnic 
background is found in table 1. 
 
SNP selection: Haplotype-tagging (ht-)SNPs were selected from the HapMap database 
(http://www.hapmap.org; version July 2006) to discriminate between all predicted common 
haplotypes (with an estimated frequency >5%) within haplotype blocks in the Central 
European sample. Haplotype blocks were defined as regions in which >85% of total 
haplotype diversity is covered by common haplotypes, using the program hapblock.13  
 
Genetic analysis: Initial SNP-genotyping on genomic DNA was performed on a TaqManTM 
platform with assays designed by Applied Biosystems. The SNP rs3754511 was genotyped 
using pyrosequencing. The genotyping of the replication sample was performed by RFLP for 
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SNPs rs2871775 and rs3754511, using HpaI and MspI restriction enzymes, respectively. 
Genotyping of rs3738815 and rs11203280 was carried out on a LightCycler (Roche 
Diagnostics). All primer sequences and experimental conditions are available from the 
authors.  
 
Statistics: First, quality control was applied to the dataset. Thus, individuals displaying a low 
call rate (one missing SNP) were removed from the analysis. SNPs passed the quality control 
when showing a call rate higher than 95%. The exact test described and implemented by 
Wigginton and colleagues was used to check for Hardy-Weinberg equilibrium (HWE).14 
Distribution of genotypes was consistent with HWE in both groups of cases and controls. 
Genotypes and allele distributions were compared between cases and controls for all SNPs 
using the global genotype test and Armitage trend test, genotypic test, dominant test, recessive 
test. To perform case-control tests on the distribution of a probabilistically inferred set, the 
haplotypes standard EM algorithm was used. All analyses were performed using the free open 
source PLINK v0.99r developed by Shaun Purcell et al.15 
 
Power calculation: A power analysis was performed with the Genetic Power calculator.16 
We estimate that, under the assumption of complete LD between the marker tested and the 
disease-causing variant, we had 77% power to detect a true difference in allele frequency 
between the 220 PD patients and 232 controls (i.e., in the first sample) with a single-marker 
association analysis (α=0.05), further assuming a frequency of the disease-associated allele A 
of 0.25, a relative risk of 1.5 for genotype Aa and of 2.25 for genotype AA, and a prevalence 
of PD in the general population over the age of 50 years of 1.5%. Using these parameters with 
both samples together the estimated power increases to 95%. 
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Results 
The initial genotyping involved 7 SNPs covering the entire ATP13A2 locus. The sample used 
for the first stage of our association analysis included a total of 452 unrelated individuals from 
Germany (Table 1). Although two SNPs failed the quality control and were omitted from the 
analysis, the remaining 5 SNPs described >90% of the most common haplotypes. Therefore, 
genotypic distributions between cases and control subjects were compared for these 5 SNPs. 
These comparisons were performed using different test models including a recessive model 
assuming homozygocity, dominant model, genotypic model, and additive model. Regardless 
which test was performed, the results for the first sample did not support a significant allelic 
or genotypic association with PD with a minimal p-value for rs11203280 of PUNC=0.134 
(Table 2). Interestingly, the same SNP showed a significant association in the men subgroup 
with an uncorrected p-value of PUNC =0.016. However, this result was not significant after 
permutation-based correction for the number of test performed (p>0.05). 
This finding prompted us to analyse a second independent sample of cases and controls. 
Especially since the initial sample had a reduced power to detect a true allelic difference. 
Thus, we genotyped the same 5 SNPs in a cohort containing 311 individuals of German and 
Serbian background (Table 1). The analysis revealed no association between this second 
sample and PD and no gender effect was observed in this second cohort (rs11203280 of 
PUNC=0.389 overall and PUNC =0.570 in men; Table 2). As expected, the analysis of both 
samples combined showed no association with PD (data not shown). To avoid any bias in the 
analysis due to population stratification in the second sample, we merged the German 
individuals from both samples to determine whether these initially observed differences were 
specific to German PD patients (Table 2). However, no positive association emerged from 
this analysis in either the complete sample and in the German men subgroup, best p-value at 
rs11203280 of PUNC =0.514 and PUNC =0.084, respectively. 
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Discussion 
We present here the data of a systematic case-control association study in two independent 
late onset PD samples. The overall results of our analysis did not support an association 
between ATP13A2 and PD. Interestingly, gender stratification of the initial sample showed a 
significant association for men with PD in the single marker analysis. Unfortunately, this 
finding did not withstand a correction for multiple testing. Nevertheless, we decided to test 
the veracity of this finding by increasing the power of detection of our study. Therefore, we 
analyzed a second independent sample of individuals with German and Serbian background. 
However, the gender effect could neither be replicated in the second sample nor in both 
samples combined. Furthermore, no gender effect was observed in the analysis of all German 
individuals from both samples. To confirm our findings, we analyzed the raw data for the 
ATP13A2 locus contained in two different genome wide association studies (GWA) 17, 18. This 
analysis revealed that all SNPs from our study were contained in one of the GWA 17 and that 
they showed no association between this ATPase gene and PD, either (data not shown). 
Interestingly, the cohort analyzed in this GWA was composed of white individuals from USA 
with an age of onset of PD ranging from 55 years to 84 years. Thus, our data combined with 
the results from Fung and colleagues strongly argue for a lack of association between 
ATP13A2 and late onset PD, at least in European and US populations. 
This negative association between SNPs within the ATP13A2 gene and PD is not a unique 
finding. Likewise, negative association were also reported for idiopathic PD and several 
common polymorphisms at gene loci involved in other monogenic forms of parkinsonism19, 
20
, with rare exceptions, such as common variants in α-synuclein.21  
In conclusion, we currently cannot conclude that common variants in the ATP13A2 locus play 
a major role in the molecular etiology of late onset PD. Yet, the question whether private 
mutations could be responsible for the PD in this age group remains open and further studies 
are warranted. 
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Legend to tables 
Table 1: General characteristics of the case control dataset. 
 
Table 2: Statistical analysis of SNPs with differential allele distribution between men and 
women 
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Table 1: General characteristics of the case control dataset.
Patient Data Control Data
Ethnic Background Gender Ethnic Background Gender
Sample
Origin
Inclusion
Criteria*
N° of
Patients German Serbian Male Female
Age of onset
±S.D.
Inclusion
Criteria
N° of
Controls German Serbian Male Female Age ± S.D.
Bonn and
Cologne,
Germany
UBBCDC 220 _ _ 153 67 60.1 ± 9(41-85)
Population from
University
Hospital Bonn
232 _ _ 105 127 69.6 ± 11.7(41-99)
Luebeck,
Germany
UBBCDC 161 123 38 126 35 51.7 ± 10,3(40-80)
Healthy
volunteers 150 119 31 97 53
53.9 ± 10,8
(40-90)
Abbreviation: UBBCDC, UK Brain Bank Clinical Diagnostic Criteria; age and standard deviation (S.D.) are given in years
*Daniel and Lees12
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Table 2: Statistical analysis of SNPs with differential allele distribution between men and women 
 
 All Males Females 
 
allele distribution(%) 
Patients  Controls 
A | B          A | B 
P-
value 
OR 
(95% CI) 
allele distribution(%) 
Patients   Controls 
A | B          A | B 
P-
value 
OR 
(95% CI) 
allele distribution(%) 
Patients   Controls 
A | B          A | B 
P-
value 
OR 
(95% CI) 
1st Sample (n=220) (n=232)   (n=153)  (n=105)   (n=67)  (n=127)   
rs3738815 18.5 | 81.5 20.1 | 79.9 0.540 0.9 (0.6-1.3) 17.0 | 83.0 23.6 | 76.4 0.065 0.7 (0.4-1.0) 22.0 | 78.0 17.0 | 83.0 0.270 1.3 (0.8-2.3) 
rs11203280 30.6 | 69.4 35.1 | 64.9 0.134 0.8 (0.6-1.1) 29.8 | 70.2 39.5 | 60.5 0.016 0.6 (0.4-0.9) 32.3 | 67.7 31.5 | 68.5 0.871 1.0 (0.7-1.6) 
2nd Sample (n=161)     (n=150)   (n=126)    (n=97)   (n=35)     (n=53)   
rs3738815 20.2 | 79.8 19.3 | 80.7 0.785 1.1 (0.7-1.6) 21.8 | 78.2 21.1 | 78.9 0.860 1.0 (0.7-1.6) 14.3 | 85.7 16.0 | 84.0 0.727 0.9 (0.4-2.0) 
rs11203280 33.5 | 66.5 30.3 | 69.7 0.389 1.2 (0.8-1.6) 36.1 | 63.9 33.5 | 66.5 0.570 1.1 (0.8-1.7) 24.3 | 75.7 24.5 | 75.5 0.969 1.0 (0.4-2.0) 
1st + 2nd Sample 
(Germans  only) 
(n=343)   (n=351)   (n=241)  (n=171)   (n=102)     (n=180)   
rs3738815 19.0 | 81.0 20.3 | 79.7 0.550 0.9 (0.7-1.2) 18.9 | 81.1 23.8 | 76.2 0.084 0.7 (0.5-1.0) 19.3 | 80.7 16.9 | 83.1 0.472 1.2 (0.8-1.8) 
rs11203280 31.9 | 68.1 33.5 | 66.5 0.514 0.9 (0.7-1.2) 32.9 | 67.1 37.7 | 62.3 0.140 0.8 (0.6-1.1) 29.5 | 70.5 29.4 | 70.6 0.989 1.0 (0.7-1.5) 
n indicates the number of tested individuals. 
P-values were obtained using the Armitage Trend Test. Results shown here are not corrected for multiple testing. CI confidence interval. Positive uncorrected p-
value is shown in bold. 
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